Inclusion Criteria:

- Patients with histologically confirmed MAIPC

- Documented progressive disease in bone, soft tissue or PSA despite castrate levels of
testosterone

- If LHRH agonist were used previously it must be kept

- Previous anti-androgen should be held at least 4 weeks for flutamida or cyproterone
and 6 weeks for bycalumida

- Previous DES should be held for at least 4 weeks before partcipating in the trial

- Chemotherapy naive patients

- No prior radioisotope

- Less than 25% of bone marrow should be irradiated for prior palliative radiotherapy

- KPS> 70%

- Adequate hematologic, hepatic and renal function

Exclusion Criteria:

- Patients with serious medical illness

- History of significant active cardiac disease

- History of gastrointestinal ulceration, bleeding or perforation

- History of myocardial infarctin within past 12 months

- Allergy to sulfonamides or to celecoxib or history of urticaria to any NSAID

The above information is not intended to contain all considerations relevant to a
patient's potential participation in a clinical trial.